- Clinical experience with durvalumab treatment2021 | First Faculty of Medicine
- Durvalumab in the treatment of lung cancer2019 | Second Faculty of Medicine
- Durvalumab in the treatment of small cell lung cancer2020 | Faculty of Medicine in Pilsen
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Adjuvant durvalumab after successful concomitant chemoradiotherapy of non-small cell lung cancer treatment2021 | Faculty of Medicine in Pilsen
- Non-small cell lung cancer radiotherapy and consolidation therapy with durvalumab2020 | Third Faculty of Medicine
- Indikace durvalumabu v léčbě pacientů s bronchogenním karcinomem2023 | First Faculty of Medicine
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study2018 | Second Faculty of Medicine
- Small cell lung cancer, current treatment and perspectives2023 | Faculty of Medicine in Pilsen
- Immunotherapy of small cell lung cancer2020 | Publication without faculty affiliation
- News in treatment of gastrointestinal cancer2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Treatment of locally advanced NSCLC in the context of current guidelines2021 | Publication without faculty affiliation
- Immunotherapy in the first line treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- ASCO 2020 virtual conference and treatment of lung cancer2020 | Publication without faculty affiliation
- Immunooncologic therapy of lung cancer. Present and perspectives2020 | Faculty of Medicine in Pilsen
- Lung cancer on virtual ASCO 20212021 | Publication without faculty affiliation
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialPublication without faculty affiliation
- Trial watch: Immune checkpoint blockers for cancer therapy2017 | Second Faculty of Medicine
- Immunotherapy in patients with small cell lung cancer, a chance for a longer and quality life - case report2023 | Third Faculty of Medicine
- Komentář k výsledkům studie PACIFIC po 3 letech terapie2020 | First Faculty of Medicine
- Komentář ke studii2020 | First Faculty of Medicine
- Treatment options for non-small cell lung stage III cancer2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Immunotherapy in small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Current procedures and news in the treatment of lung cancer2021 | First Faculty of Medicine
- Imunooncologic therapeutic options in small cell lung cancer (SCLC) therapy2020 | Faculty of Medicine in Pilsen
- News in the treatment of small cell lung cancer2022 | Faculty of Medicine in Pilsen
- Immunotherapy in the treatment of lung cancer2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Is anticancer immunotherapy break-trough in lung cancer therapy?2019 | First Faculty of Medicine
- Is anticancer imunotherapy break-trough in lung cancer therapy?2020 | First Faculty of Medicine